Table 4.
Prognostic factors
| Factors | n | 5-year OS | P-value | |
|---|---|---|---|---|
| Univariate | Multivariate | |||
| Age (years) | ||||
| <66 | 24 | 67% | 0.036 | 0.145 |
| ≥66 | 25 | 48% | ||
| Performance status score | ||||
| 0 | 41 | 61% | 0.052 | 0.102 |
| 1 | 8 | 38% | ||
| Gender | ||||
| Male | 42 | 57% | 0.834 | |
| Female | 7 | 57% | ||
| Body mass index | ||||
| <20.5 | 26 | 38% | 0.012 | 0.007 |
| ≥20.5 | 23 | 78% | ||
| DM history | ||||
| Yes | 6 | 67% | 0.535 | |
| No | 43 | 56% | ||
| CVD history | ||||
| Yes | 18 | 56% | 0.407 | |
| No | 31 | 58% | ||
| Tumor location | ||||
| Upper/Middle | 32 | 56% | 0.408 | |
| Lower/EGJ | 17 | 59% | ||
| Tumor length (cm) | ||||
| <5.0 | 26 | 54% | 0.772 | |
| ≥5.0 | 23 | 61% | ||
| T-factor | ||||
| 1–2 | 8 | 75% | 0.473 | |
| 3 | 41 | 53% | ||
| N-factor | ||||
| Negative | 10 | 90% | 0.013 | 0.008 |
| Positive | 39 | 49% | ||
| Clinical stage | ||||
| I–II | 14 | 79% | 0.070 | 0.442 |
| III | 35 | 49% | ||
| CEA value | ||||
| Normal | 44 | 59% | 0.624 | |
| High | 5 | 40% | ||
| SCC antigen value | ||||
| Normal | 24 | 63% | 0.506 | |
| High | 25 | 52% | ||
| Hemoglobin value | ||||
| Normal | 36 | 61% | 0.272 | |
| Low | 13 | 46% | ||
| Albumin value | ||||
| Normal | 39 | 62% | 0.116 | |
| Low | 10 | 40% | ||
| Initial SUVmax value | ||||
| <10 | 24 | 54% | 0.939 | |
| ≥10 | 25 | 60% | ||
| %ΔSUVmax (%) | ||||
| <72 | 23 | 39% | 0.034 | 0.020 |
| ≥72 | 26 | 73% | ||
| Course of chemotherapy | ||||
| 1 course | 15 | 50% | 0.706 | |
| 2 courses | 34 | 61% | ||
OS = overall survival, DM = diabetes mellitus, CVD = cardiovascular disease, CEA = carcinoembryonic antigen, SCC = squamous cell carcinoma, SUV = standardized uptake value